

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3851231

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	ALNYLAM EUROPE AG	08/05/2009
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	ALNYLAM PHARMACEUTICALS, INC.	
<b>Street Address:</b>	300 THIRD STREET	
<b>City:</b>	CAMBRIDGE	
<b>State/Country:</b>	MASSACHUSETTS	
<b>Postal Code:</b>	02142	
<b>PROPERTY NUMBERS Total: 3</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	14737304	
<b>Patent Number:</b>	9074213	
<b>Patent Number:</b>	8546143	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(650)938-5200	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	650-335-7185	
<b>Email:</b>	nmorad@fenwick.com	
<b>Correspondent Name:</b>	ANTONIA L. SEQUEIRA	
<b>Address Line 1:</b>	FENWICK & WEST LLP	
<b>Address Line 2:</b>	801 CALIFORNIA STREET	
<b>Address Line 4:</b>	MOUNTAIN VIEW, CALIFORNIA 94041	
<b>ATTORNEY DOCKET NUMBER:</b>	26421-29705/US	
<b>NAME OF SUBMITTER:</b>	ANTONIA L. SEQUEIRA, REG 54670	
<b>SIGNATURE:</b>	/Antonia L. Sequeira/	
<b>DATE SIGNED:</b>	04/28/2016	
<b>Total Attachments: 3</b>		
source=29705_US_Assignment_ALN_AG_to_ALN_Inc#page1.tif		
source=29705_US_Assignment_ALN_AG_to_ALN_Inc#page2.tif		
source=29705_US_Assignment_ALN_AG_to_ALN_Inc#page3.tif		

## ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, ALNYLAM EUROPE AG, a German company, c/o Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, MA 02142 ("ASSIGNOR"), has sold, assigned, and transferred and does hereby sell, assign, and transfer to Alnylam Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 300 Third Street, Cambridge, MA 02142, ("ASSIGNEE"), for itself and its successors, transferees, and assignees, the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the provisional applications filed under 35 U.S.C. §111(b) or non-provisional applications filed under 35 U.S.C. §111(a) or U.S. national phase application filed under 35 U.S.C. § 371 and listed in the attached APPENDIX A ("APPLICATIONS").

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATIONS; (b) all applications claiming priority from the APPLICATIONS; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATIONS and in any underlying provisional or foreign application, together with all rights to recover damages for infringement of provisional rights.

ASSIGNOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNOR or ASSIGNEE'S own name.

ASSIGNOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute and/or cause to be executed all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. ASSIGNOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the ASSIGNOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

ASSIGNOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.


This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

This Assignment is effective at least as of the filing date or the earliest claimed priority date of the APPLICATION.

Duly Authorized Representative of ASSIGNOR

Name and Signature

Date of Signature



8/5/09, 2009

Donna Ward, Ph.D., J.D.

Title: Vorstund

Vice President, Intellectual Property

Appendix A: U.S. Patent Applications assigned from  
Alnylam Europe AG to Alnylam Pharmaceuticals, Inc.

<u>Fenwick Ref. No.</u>	<u>Client Ref. No.</u>	<u>File Date</u>	<u>Application Number</u>	<u>Application Title</u>
26421-15768/US	RIB-001.3-US- CON1	31-Oct-07	11/982,325	METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A GIVEN GENE
26421-15769/US	RIB-001.3-US- CON2	31-Oct-07	11/982,305	METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A GIVEN GENE
26421-15770/US	RIB-001.3-US- CON3	31-Oct-07	11/982,425	METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A GIVEN GENE
26421-15771/US	RIB-001.3-US- CON4	31-Oct-07	11/982,441	METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE
26421-15772/US	RIB-001.3-US- CON5	31-Oct-07	11/982,345	METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A GIVEN GENE
26421-15773/US	RIB-001.3-US- CON6	31-Oct-07	11/982,434	METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A GIVEN GENE
26421-15774/US	RIB-001.3-D1	6-Mar-03	10/382,395	METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A GIVEN GENE
26421-15775/US	RIB-001.3-D2	6-Mar-03	10/383,099	METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A GIVEN GENE
26421-15776/US	RIB-001.3-D3	6-Mar-03	10/382,768	METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A GIVEN GENE
26421-15777/US	RIB-001.3-D4	2-Jul-03	10/612,179	METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A GIVEN GENE
26421-15795/US	RIB-002.4	7-Mar-03	10/384,339	COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE
26421-15797/US	RIB-006.2-US	7-Mar-03	10/384,260	COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI-APOPTOTIC GENES
26421-15802/US	RIB-008.2	7-Mar-03	10/384,512	COMPOSITIONS AND METHODS FOR INHIBITING VIRAL REPLICATION
26421-15803/US	RIB-008.3-US- 00	19-Dec-07	11/959,936	COMPOSITIONS AND METHODS FOR INHIBITING VIRAL REPLICATION